Sonoma Pharmaceuticals shares rise 13.76% premarket after reporting 57% revenue growth, beating estimates, and launching new products with regulatory approvals.

Sonoma Pharmaceuticals Inc. surged 13.76% in premarket trading following the release of robust second fiscal quarter 2026 results. The company reported a 57% year-over-year revenue increase to $5.6 million, driven by a 115% rise in U.S. sales of over-the-counter products and new product launches, including HOCl-based diaper rash treatments and a FDA-registered facial spray. Regulatory milestones, such as the National Psoriasis Foundation endorsement and a hospital-distributed wound cleanser, further bolstered confidence. Earnings highlighted a 46% reduction in net loss per share and a narrowing EBITDA loss, with the CEO emphasizing strong growth momentum. Analysts cited improved profitability, a "strong buy" rating, and a $14.80 price target, contributing to the sharp premarket rally.